SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Braddock Bull who wrote (2547)2/26/1998 11:07:00 AM
From: Dauntless  Read Replies (2) of 7041
 
Braddock Bull - food for thought

You're absolutely correct about the slanted nature of the Asensio report - ALL of his reports have been "manipulated" to cast doubts upon Zonagen's ethics, etc.

As to the patent application & the lawsuit. As it's an ongoing legal proceeding, I'd rather not talk about it directly.

In my experience, as far as general rule in patent strategy, it is felt by many that an initial patent application should be as "far reaching" as possible. In fact, a patent application that gets all of its claims granted on the first round is generally thought to be a "poor" application - i.e., it didn't include broad enough claims. Typically, among all the claims filed for, there will be some that are rejected as prior art, etc. - this implies that you have "slightly exceeded" the claims that you're entitled to. The patent examiner will whittle it down for you - in fact, you'll probably spend lots of money educating him to grant what is rightfully yours.

All IMHO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News